Contact:
4008465777
-
About Us
News & Events
-
08-22
Tonghua Dongbao: Recovery growth in operational performance in H1 2023
On the evening of August 21, 2023, Tonghua Dongbao Pharmaceutical Co., Ltd. ("Tonghua Dongbao" or the "Company") released its semi-annual report for 2023. In H1 2023, the Company's revenue stood a...
-
06-01
Tonghua Dongbao: First subject enrolled in Phase I clinical trial on first Chinese-made dual-target inhibitor for gout (THDBH151 Tablets)
Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd. ("Dongbao Zixing"), a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company" or "Tonghua Dongbao") received the notice...
-
04-27
Tonghua Dongbao: Product sales continue to grow in Q1 2023
Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its Q1 2023 results on April 26. During the reporting period, the ...
-
04-22
For ten consecutive years | Tonghua Dongbao publishes 2022 CSR Report
On April 20, Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2022 Corporate Social Responsibility (CSR) Report...
-
04-21
Tonghua Dongbao: Product sales show steady growth in 2022, securing the largest human insulin market share in China
Tonghua Dongbao Pharmaceutical Co., Ltd. (stock code: 600867, hereinafter referred to as "Tonghua Dongbao" or the "Company") released its 2022 Annual Report on April 20. In 2022, the Company recorded ...
-
02-08
Tonghua Dongbao: First subject enrolled in Phase II clinical trial on novel URAT1 inhibitor (THDBH130 Tablets) for gout
Recently, Dongbao Zixing (Hangzhou) Biopharmaceutical Co., Ltd., a wholly owned subsidiary of Tonghua Dongbao Pharmaceutical Co., Ltd. ("the Company") has enrolled the first subject in the Phase II cl...